Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
13 dic 2022
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: review
Pubblicato online: 13 dic 2022
Pagine: 409 - 419
Ricevuto: 19 ott 2022
Accettato: 27 ott 2022
DOI: https://doi.org/10.2478/raon-2022-0049
Parole chiave
© 2022 Anze Smole, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Smole, Anze
Immunology and Cellular Immunotherapy (ICI) Group, Department of Genetic Toxicology and Cancer Biology, National Institute of BiologyLjubljana, Slovenia